311 related articles for article (PubMed ID: 30580378)
1. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.
Conway AM; Mitchell C; Kilgour E; Brady G; Dive C; Cook N
Br J Cancer; 2019 Jan; 120(2):141-153. PubMed ID: 30580378
[TBL] [Abstract][Full Text] [Related]
2. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
3. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy: a new diagnostic, predictive and prognostic window in cancers of unknown primary.
El Rassy E; Khaled H; Pavlidis N
Eur J Cancer; 2018 Dec; 105():28-32. PubMed ID: 30388661
[TBL] [Abstract][Full Text] [Related]
5. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
[TBL] [Abstract][Full Text] [Related]
6. TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary.
Shen Y; Chu Q; Yin X; He Y; Bai P; Wang Y; Fang W; Timko MP; Fan L; Jiang W
Brief Bioinform; 2021 Mar; 22(2):2106-2118. PubMed ID: 32266390
[TBL] [Abstract][Full Text] [Related]
7. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
8. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.
Varadhachary G
Clin Cancer Res; 2013 Aug; 19(15):4027-33. PubMed ID: 23519898
[TBL] [Abstract][Full Text] [Related]
9. Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.
Pentheroudakis G; Spector Y; Krikelis D; Kotoula V; Meiri E; Malamou-Mitsi V; Fountzilas G; Sanden M; Pavlidis N; Benjamin H; Aharonov R
Clin Exp Metastasis; 2013 Apr; 30(4):431-9. PubMed ID: 23124598
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
11. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
Lorkowski SW; Dermawan JK; Rubin BP
Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
[TBL] [Abstract][Full Text] [Related]
12. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
Greco FA
Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
[TBL] [Abstract][Full Text] [Related]
14. Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).
Es HA; Mahdizadeh H; Asl AAH; Totonchi M
Sci Rep; 2021 Jul; 11(1):15112. PubMed ID: 34302033
[TBL] [Abstract][Full Text] [Related]
15. Genetic characterisation of molecular targets in carcinoma of unknown primary.
Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
[TBL] [Abstract][Full Text] [Related]
16. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.
Moran S; Martinez-Cardús A; Boussios S; Esteller M
Nat Rev Clin Oncol; 2017 Nov; 14(11):682-694. PubMed ID: 28675165
[TBL] [Abstract][Full Text] [Related]
17. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic challenges of patients with carcinoma of unknown primary.
Rassy E; Pavlidis N
Expert Rev Anticancer Ther; 2020 Sep; 20(9):775-783. PubMed ID: 32779501
[TBL] [Abstract][Full Text] [Related]
19. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
Ma W; Wu H; Chen Y; Xu H; Jiang J; Du B; Wan M; Ma X; Chen X; Lin L; Su X; Bao X; Shen Y; Xu N; Ruan J; Jiang H; Ding Y
Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343328
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
